A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

Inclusion Criteria:

• Male or female

• Age above or equal to 18 years at the time of signing informed consent

• BMI greather than or equal to 27.0 kg/m^2

• Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days beforescreening

• Treatment with either lifestyle intervention, or treatment with 1-3 marketed oralantidiabetic drugs (OAD)s (metformin, α-glucosidase inhibitors (AGI), glinides,sodium-glucose co-transporter 2 inhibitor (SGLT2i), thiazolidinediones, orsulphonylureas (SU)s as a single agent or in combination) according to local label

• Treatment with oral antidiabetic drugs should be stable (same drug(s), dose anddosing frequency) for at least 90 days before screening

• HbA1c 7%-10% (53-86 mmol/mol) (both inclusive) as measured by the central laboratoryat screening

Exclusion Criteria:

• Clinically significant or severe hypoglycaemia within 6 months before screening orhistory of hypoglycaemia unawareness

• Renal impairment with estimated glomerular filtration rate (eGFR) below 30mL/min/1.73 m^2, as measured by the central laboratory at screening

• Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verifiedby a fundus examination performed within 90 days before screening or in the periodbetween screening and randomisation. Pharmacological pupil-dilation is a requirementunless using a digital fundus photography camera specified for non-dilatedexamination.